目的 探究血脂康胶囊联合依那普利和硝苯地平治疗高血压合并冠心病的临床疗效。方法 收集2014年1月—2015年1月于海南省万宁市人民医院就诊的高血压合并冠心病患者100例,根据治疗方案的不同分为对照组和治疗组,每组各50例。对照组口服硝苯地平控释片,1片/次,1次/d,口服马来酸依那普利片,初始剂量为1片/次,1次/d,2周后1片/次,2次/d。治疗组在对照组的基础上口服血脂康胶囊,2粒/次,2次/d。两组患者均连续治疗2个月。观察两组的临床疗效,比较两组治疗前后血压、血脂的变化情况。结果 治疗后,对照组和治疗组的降压总有效率分别为80.0%、92.0%;两组降脂总有效率分别为80.0%、94.0%;两组心电图总有效率分别为76.0%、88.0%;两组心绞痛总有效率分别为74.0%、90.0%,两组总有效率比较差异具有统计学意义(P<0.05)。治疗后,两组患者收缩压、舒张压、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)均显著降低,高密度脂蛋白胆固醇(HDL-C)显著升高,同组治疗前后差异具有统计学意义(P<0.05);且治疗组这些观察指标的改善程度优于对照组,两组比较差异具有统计学意义(P<0.05)。结论 血脂康胶囊联合依那普利和硝苯地平治疗高血压合并冠心病患者的临床疗效确切,安全性高,能够有效改善患者的血压及血脂情况,具有一定的临床推广应用价值。

Objective To explore the clinical effect of Xuezhikang Capsules combined with enalapril and nifedipine in treatment of hypertension with coronary heart disease. Methods Patients (100 cases) with hypertension with coronary heart disease in People's Hospital of Wanning in Hainan Province from January 2014 to January 2015 were enrolled in this study. According to the different treatment plans, patients were divided into treatment group (50 cases) and control group (50 cases). The patients in the control group were po administered with Nifedipine Controlled Release Tablets, 1 tablet/time, once daily. And they were po administered with Enalapril Maleate Tablets, initial dosage was 1 tablet/time, once daily, after 2 weeks the dosage was 1 tablet/time, twice daily. The patients in the treatment group were po administered with Xuezhikang Capsules on the basis of control group, 2 grains/time, twice daily. The patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the changes of blood pressure and blood lipid in two groups were compared. Results After treatment, the depressurization efficacies in the control and treatment groups were 80.0% and 92.0%, respectively; The lipid-decreasing efficacies in the control and treatment groups were 80.0% and 94.0%, respectively; Electrocardiogram total effective rate in two groups were 76.0% and 88.0%, respectively; Angina total effective rate in two groups were 74.0% and 90.0%, respectively, and there were differences between two groups (P < 0.05). After treatment, systolic pressure, diastolic blood pressure, TC, TG, and LDL-C in two groups were significantly decreased, but HDL-C was significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xuezhikang Capsule combined with enalapril and nifedipine has clinical curative effect with high safety, and can effectively improve the blood pressure and blood lipid of patients, which has a certain clinical application value.